8-K - Alzamend Neuro, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Alzamend Neuro, Inc. entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC on March 6, 2026, to sell up to $3.0 million of common stock through an ATM Offering pursuant to its effective Form S-3 registration statement. The Company filed a prospectus supplement with the SEC on the same date.

Key Takeaways

1Entered At-the-Market Issuance Sales Agreement on March 6, 2026

2Sales agent: Ascendiant Capital Markets, LLC

3Aggregate offering price: up to $3.0 million of common stock (par value $0.0001)

4ATM Offering under Rule 415, Registration Statement No. 333-273610 (effective August 10, 2023)

5Filed prospectus supplement with SEC on March 6, 2026

6Exhibits: 5.1 (Olshan Frome Wolosky LLP opinion), 10.1 (Sales Agreement)

Current Report Details

Event Type

Material Agreement

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On March 6, 2026, Alzamend Neuro, Inc. (the “ Company ”) entered into an At-the-Market Issuance Sales Agreement (the

Material Agreement

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Olshan Frome Wolosky LLP. 10.1 At-The-Market Issuance Sales Agreement, da

Exhibits Only

Transaction Details

Material Agreement

Agreement: At-the-Market Issuance Sales Agreement
Parties: Alzamend Neuro, Inc., Ascendiant Capital Markets, LLC (sales agent)

•Sell shares of common stock with aggregate offering price up to $3.0 million
•Through at-the-market offering as defined in Rule 415 under Securities Act
•Agent uses commercially reasonable efforts to sell based on Company instructions
•Company sets parameters including number of shares, time period, daily limits, minimum price
•Either party may suspend or terminate upon notice

Exhibits (3)

10.1

EXHIBIT 10.1

5.1

EXHIBIT 5.1

8-K

Exhibit